Actively Recruiting
Partial Pleurectomy (Surgery) for Unresectable Pleural Mesothelioma
Led by University of Chicago · Updated on 2026-02-17
30
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Purpose of the study: The main purpose of this research study is to see if a surgery procedure (limited partial pleurectomy and decortication) helps symptoms in people who have cancer that is unresectable that might not be able to be removed completely. This is called unresectable cancer. This study will also help the research team learn more about the types of symptoms and quality of life for people who have undergone this surgery, the number of complications following , and the time from surgery to starting other therapy. Th e study team also wants to see see the overall survival of people who have had this procedure as part of their care. What will be done as part of research on this study: * Surgery (Partial Pleurectomy - surgery to remove lining of lungs) * The research team will also ask study participants questions about their symptoms through questionnaires at certain times after surgery. How long this study will last: Participation in this research (pre-surgery, surgery and follow-up) will last for about 2 years. Confidentiality: All personal information will be kept confidential, and data will be used only for research purposes. Contact Information: For more information about this study, please contact PhaseIICRA@medicine.bsd.uchicago.edu
CONDITIONS
Official Title
Partial Pleurectomy (Surgery) for Unresectable Pleural Mesothelioma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed epithelioid subtype pleural mesothelioma by surgical biopsy
- Disease confined to one side of the chest (unilateral hemithorax)
- Disease classified as unresectable or borderline resectable based on imaging
- Successful completion of at least 6 weeks of systemic induction therapy without unresolved adverse events precluding surgery
- Age 18 years or older
- ECOG performance status 0 or 1
- Adequate organ and marrow function as defined by specified blood and liver test values
- HIV patients on effective therapy with undetectable viral load within 6 months
- Patients with controlled hepatitis B or cured hepatitis C infection
- Cardiac function assessed as New York Heart Association Functional Classification class 2B or better
- Review by multidisciplinary treatment conference
- Prior or concurrent enrollment in UChicago's Mesothelioma Biobank
- Ability and willingness to sign informed consent
You will not qualify if you...
- Biphasic or sarcomatoid pleural mesothelioma
- Metastatic disease or disease extending to abdomen or below diaphragm
- Disease progression during or after induction therapy
- Lung function with FEV1 less than 50% or predicted DLCO less than 50%
- Receiving other investigational agents
- Uncontrolled intercurrent illness
- Active malignancy within 2 years prior to registration except certain cured cancers
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Chicago Medicine Comprehensive Cancer Center
Chicago, Illinois, United States, 60637
Actively Recruiting
Research Team
C
Cancer Trials Intake
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here